FI104233B1 - Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi - Google Patents

Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi

Info

Publication number
FI104233B1
FI104233B1 FI920132A FI920132A FI104233B1 FI 104233 B1 FI104233 B1 FI 104233B1 FI 920132 A FI920132 A FI 920132A FI 920132 A FI920132 A FI 920132A FI 104233 B1 FI104233 B1 FI 104233B1
Authority
FI
Finland
Prior art keywords
vaccine compositions
preparation
compositions containing
interleukins
interleukin
Prior art date
Application number
FI920132A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI104233B (fi
FI920132A0 (fi
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of FI920132A0 publication Critical patent/FI920132A0/fi
Application granted granted Critical
Publication of FI104233B publication Critical patent/FI104233B/fi
Publication of FI104233B1 publication Critical patent/FI104233B1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI920132A 1989-07-14 1992-01-13 Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi FI104233B1 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14
US37974289 1989-07-14
US9003982 1990-07-16
PCT/US1990/003982 WO1991001143A1 (en) 1989-07-14 1990-07-16 Stable vaccine compositions containing interleukins

Publications (3)

Publication Number Publication Date
FI920132A0 FI920132A0 (fi) 1992-01-13
FI104233B FI104233B (fi) 1999-12-15
FI104233B1 true FI104233B1 (fi) 1999-12-15

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920132A FI104233B1 (fi) 1989-07-14 1992-01-13 Menetelmä stabiilien, interleukiineja sisältävien rokotekoostumusten valmistamiseksi

Country Status (12)

Country Link
EP (1) EP0482076B1 (da)
JP (2) JP3485184B2 (da)
KR (1) KR0177179B1 (da)
AT (1) ATE121629T1 (da)
AU (1) AU648509B2 (da)
CA (1) CA2063587C (da)
DE (1) DE69018990T2 (da)
DK (1) DK0482076T3 (da)
ES (1) ES2075900T3 (da)
FI (1) FI104233B1 (da)
NO (1) NO301577B1 (da)
WO (1) WO1991001143A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
DE69032484D1 (de) * 1989-10-27 1998-08-20 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
DK0563254T3 (da) * 1990-12-19 1996-02-12 Schering Corp Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
WO1992020370A1 (en) * 1991-05-13 1992-11-26 Regents Of The University Of California Liposomal polysaccharide vaccines
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
ATE151989T1 (de) * 1992-08-10 1997-05-15 Us Gov Health & Human Serv Interleukin-4 stimulierter t-lymphozyten-zelltod
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
AU724743B2 (en) * 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP2003515569A (ja) 1999-12-03 2003-05-07 セルテック アール アンド ディ リミテッド ワクチンアジュバントとして有用なインターロイキン−１ムテイン
US8663634B2 (en) 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
JP2009510032A (ja) * 2005-09-30 2009-03-12 リポクセン テクノロジーズ リミテッド 多糖抗原及びタンパク質アジュバントを含む多価リポソームワクチン組成物
JP2009544761A (ja) 2006-06-14 2009-12-17 マクロジェニクス，インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
AU2008226974B2 (en) * 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
EP2925297B1 (en) * 2012-11-02 2017-06-21 CyTuVax Composition comprising cytokine macro-aggregates
KR102822878B1 (ko) * 2018-10-12 2025-06-20 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 감소된 용량의 불활성화된 폴리오바이러스를 포함하는 조합 백신 조성물 및 그의 제조 방법
CA3119341A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
AU2021207586A1 (en) 2020-01-13 2022-07-21 Neoimmunetech, Inc. Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2022093718A1 (en) 2020-10-26 2022-05-05 Neoimmunetech, Inc. Methods of inducing stem cell mobilization
KR20230104176A (ko) 2020-11-02 2023-07-07 네오이뮨텍, 인코퍼레이티드 코로나바이러스의 치료를 위한 인터류킨-7의 용도
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
CN119836296A (zh) 2021-12-30 2025-04-15 新免疫技术有限公司 用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
FI104233B (fi) 1999-12-15
ES2075900T3 (es) 1995-10-16
NO301577B1 (no) 1997-11-17
KR0177179B1 (ko) 1999-03-20
CA2063587C (en) 2005-08-30
JP3485184B2 (ja) 2004-01-13
EP0482076A1 (en) 1992-04-29
ATE121629T1 (de) 1995-05-15
AU6050090A (en) 1991-02-22
DE69018990T2 (de) 1995-12-14
WO1991001143A1 (en) 1991-02-07
EP0482076B1 (en) 1995-04-26
AU648509B2 (en) 1994-04-28
DK0482076T3 (da) 1995-07-17
NO920161L (no) 1992-03-05
DE69018990D1 (de) 1995-06-01
KR920703103A (ko) 1992-12-17
FI920132A0 (fi) 1992-01-13
JPH04506663A (ja) 1992-11-19
CA2063587A1 (en) 1991-01-15
JP2004002463A (ja) 2004-01-08
NO920161D0 (no) 1992-01-13

Similar Documents

Publication Publication Date Title
DK0482076T3 (da) Stabile vaccinepræparater indeholdende interleukiner
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
GR76073B (da)
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
RU94046145A (ru) Комбинированные вакцины, содержащие поверхностный антиген гепатита в и другие антигены, способ их получения, способ предупреждения инфекций гепатита в
NO971792D0 (no) Blanding inneholdende en aerogel, dens fremstilling og anvendelse
ES2092306T3 (es) Adyuvante para vacunas.
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
DE69427824D1 (de) Impfstoffe bestehend aus protein- oder peptid-"cochleaten" und deren verwendung zur immunisierung
NO924103D0 (no) Anvendelse av antistoffholdig preparater for immunundertrykkelse
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
NO165478C (no) Fremgangsmaate for fremstilling av antigeniske preparater.
EP0994721A4 (en) NERVOUS GROWTH FACTOR AS A VACCINE ADDITIVE
AU3449884A (en) Preparation of vaccines comprising antigens bound to glycoside containing carriers
NZ189756A (en) Muramyl peptides antigens covalently bonded to muramyl-peptides medicaments and vaccines
NZ203190A (en) Vaccines of infections bronchitis virus
AU7412887A (en) A structural phosphoprotein (PP 15) of human cytomegalovirus, and the preparation and use thereof
ZA813479B (en) Process for the isolation of viral glycoproteic antigens and its application to the preparation of vaccines
FI915702A7 (fi) Peptidejä ja niistä johdettuja vasta-aineita HTLV-1 infektion vastaise n rokotuksen määrittämiseksi
AU8298991A (en) Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
SE8404334L (sv) 16-fluoro-16,17-didehydro-prostanoider och forfarande for deras framstellning
IT1135680B (it) Procedimento per la manipolazione di prodotti stampati,come pure mezzi e dispositivo per l'esecuzione dello stesso

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: AMERICAN CYANAMID COMPANY

MA Patent expired